Method for enhancing or inhibiting insulin-like growth factor-I

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8206706
APP PUB NO 20090226452A1
SERIAL NO

12388045

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLCHAPEL HILL, NC707

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Clemmons, David R Chapel Hill, US 13 66
Maile, Laura A Chapel Hill, US 11 62

Cited Art Landscape

Patent Info (Count) # Cites Year
 
APPLIED MOLECULAR EVOLUTION, INC. (3)
6531580 Anti-.alpha.v.beta.3 recombinant human antibodies and nucleic acids encoding same 25 1999
7371382 Methods of inhibiting .alpha..sub.v.beta..sub.3-mediated binding with .alpha..sub.v.beta..sub.3-specific antibodies 7 2002
7422744 Methods of treating cancer with alphavbeta3-specific antibodies 7 2003
 
GENENTECH, INC. (1)
5578704 Antibody to osteoclast alphavbeta3 ntegrin 28 1994
 
IXSYS, INC. (2)
6590079 Anti-.alpha.v.beta.3 recombinant human antibodies, nucleic acids encoding same 10 1997
6596850 Anti-.alpha.v3.beta.3 recombinant human antibodies, nucleic acids encoding same 11 1998
 
Research Foundation for the State University of N.Y. (1)
5336618 Fibrinogen blocking monoclonal antibody 11 1988
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (1)
6887473 Inhibition of angiogenesis in disease states with an anti-αvβ3 monoclonal antibody 12 1998
 
The Scripps Research Institute (2)
5753230 Methods and compositions useful for inhibition of angiogenesis 74 1994
7354586 Methods of treating arthritis and diabetic retinopathy with .alpha..sub.v.beta..sub.3-specific antibodies 7 2004
 
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (2)
7723483 Method for enhancing or inhibiting insulin-like growth factor-I 8 2005
2009/0280,127 MONOCLONAL ANTIBODIES FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR-I 3 2009
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
INHIBRX LLC (1)
9045541 CD47 antibodies and methods of use thereof 6 2013
 
INHIBRX LP (1)
9663575 CD47 antibodies and methods of use thereof 0 2015
 
SAMSUNG ELECTRONICS CO., LTD. (1)
9194816 Method of detecting a defect of a substrate and apparatus for performing the same 0 2014
 
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (3)
9068000 Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I 1 2012
9073996 Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1) 1 2013
9587024 Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1) 0 2015
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 26, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 26, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00